Details werden geladen...
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes | The M...
In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placeboSimilar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) diseasePivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA) SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.
Ähnliche Seiten
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-pws-at-endo-2026/2364858
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/madrigal-presents-data-demonstrating-rezdiffra-reduced-markers-of-cardiovascular-and-liver-related-risk-in-patients-with-mash/2352596New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer/2345762Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/galectin-therapeutics-presents-new-easl-2026-oral-and-poster-analyses-demonstrating-belapectins-potential-to-modify-disease-progression-in-advanced-mash-cirrhosis/2352558Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting |...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1ab-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma-and-colorectal-cancer-at-the-2026-asco-meeting/2349695